Streptococcus agalactiae, or group B streptococcus (GBS), infects diverse hosts including humans, economically important livestock and fishes. In the context of human health, GBS is a major cause of neonatal infections and an emerging cause of invasive disease in adults. Here we show that GBS is able to establish a systemic infection in G. mellonella larvae that is associated with extensive bacterial replication and dose dependent larval survival. This infection model is suitable for use with GBS isolates from both homeothermic and poikilothermic hosts and a hypervirulent sequence type (ST) associated with invasive human disease, ST283, shows increased virulence in this model, indicating it may be useful in studying GBS virulence determinants. In addition, we demonstrate that larval survival can be afforded by antibiotic treatment and so the model may also be useful in the development of novel anti-GBS strategies.
Introduction
Streptococcus agalactiae, or Group B Streptococcus (GBS) is a Gram-positive multi-host pathogen and a major cause of human neonatal infections and mortality. GBS was initially described in 1887 as an animal pathogen responsible for mastitis in ruminants and although largely eradicated in some countries with a highly developed dairy industry, remains a major cause of bovine mastitis in many countries 1 . In 1966, GBS infection of fish was reported in the USA 2 with subsequent outbreaks described in fish farms in Asia and the Americas 3, 4 . GBS infection is often associated with high levels of mortality in fish and with the worldwide growth of aquaculture has significant economic impact 5 . In the 1970s GBS was described as the leading cause of human neonatal infectious morbidity and mortality with two distinct GBS-associated syndromes: earlyonset disease occurring 0-6 days after birth and late-onset disease occurring 7 days -3 months after birth 6, 7 . The implementation of routine antibiotic prophylaxis during labour in many countries has resulted in a decrease of the incidence of early-onset disease, although the number of cases of late-onset disease has remained stable or even increased in some countries 7, 8 .
GBS is also recognized as an emerging pathogen in adults that is associated with increasing fatality rates, reaching 15% in developed countries 9, 10, 11 . Adult GBS infections are often associated with underlying co-morbidities but a recent foodborne outbreak of invasive GBS disease in adults in Singapore was linked to the consumption of infected fish and occurred in previously healthy adults 12, 13 . Despite some level of host adaptation, e.g. association of sequence type (ST) 67 with cattle 14 and association of ST7, ST283 and clonal complex (CC) 552 with poikilothermic animals 15 , host-association is not absolute and interspecies transmission between people, cattle and fish may occur 12, 16, 17 .
The routine use of antibiotic prophylaxis in pregnant women carrying GBS in many countries and routine use of antimicrobials in aquaculture and dairy farming may all exert selective pressure that favours emergence of antimicrobial resistance (AMR) in GBS 18 . Currently there is no GBS vaccine commercially available for human or bovine use and available fish vaccines do not confer protection against some serotypes. Consequently, the development of alternative anti-GBS strategies is of prime importance 19 .
A number of in vivo models exists for GBS infection (mice, rats, zebra fish) and are valuable for the study of host-pathogen interactions and virulence 20, 21, 22 . Here, we evaluate the use of Galleria mellonella larvae as an in vivo model of infection for GBS by testing their susceptibility to human, bovine or fish GBS isolates encompassing hostassociated and multi-host STs. We also determine the utility of G. mellonella larvae for in vivo screening of antimicrobial efficacy during GBS infection.
Results

G. mellonella larvae are susceptible to GBS infection
To begin to assess the suitability of G. mellonella larvae as an infection model for GBS strains isolated from its major hosts, we tested the susceptibility of larvae to dose-dependent killing by GBS strains from human, bovine and piscine origin. Larvae were challenged with serial dilutions of two isolates of ST17 (bovine strain MRI Z1-363, human MRI Z2-093) and one isolate of ST283
(piscine STIR CD25). Infected larvae were incubated at 37°C and survival was monitored 18h, 24h
and 48h post-infection ( Figure 1A-C) . All three strains induced a dose-dependent response that was reproducible for each strain in three independent experiments. Immunohistochemical analysis of infected larvae with an anti-GBS antibody indicated extensive bacterial replication within larvae during the course of infection ( Figure 1D ). To generate quantitative data on the extent of GBS replication, CFU counts from homogenised infected larvae were measured for the piscine ST283 strain STIR CD25 ( Figure 1E ). CFU counts show extensive growth of ST283 up to 8 hours post infection, which is followed by a stationary phase of growth.
To further asses the utility of this model across a range of GBS strains, we tested the susceptibility of larvae to the fish specific ST260 isolate STIR CD10. Unlike piscine isolates of ST283, ST260 strains grow optimally at 28°C and does not grow at 37°C. Similar to experiments with non-ST260 strains at 37°C, STIR CD10 displayed dose dependent killing of G. mellonella larvae at 28°C (Figure 2A ). To determine if incubation temperature is a critical parameter in determining the course of infection as has been previously described for a Galleria model of
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, one ST283 isolate (strain MRI Z2-366) was used to challenge larvae at both 28°C and 37°C. Percentage survival 24 h and 48 h post infection were similar at both temperatures, suggesting that the temperature of incubation post-challenge does not greatly influence virulence of GBS in this model ( Figure 2B ).
Invasive ST283 strains show increased virulence in G. melonella
Next, we examined if isolates from different host species showed different levels of virulence in G. melonella larvae through determination of the LD 50 for GBS strains of human (n=9), bovine (n=12) and piscine origin (n=13). For each host species, we selected strains from the major epidemiologically relevant capsular serotypes and clonal complexes ( showed that there is a significant difference in virulence between these two groups ( Figure 3B ).
Antibiotic treatment rescues larvae infected with susceptible strains
To test the utility of the Galleria model to screen for antibiotic efficacy against GBS infection in vivo we tested the ability of erythromycin, ampicillin and tetracycline to afford survival against a lethal GBS infection. The three antibiotics were tested against 4 fish isolates (ST7, ST283, ST500, ST260), 2 human isolates (ST17, ST8) and 3 bovine isolates (ST8, ST7 and ST17). One ST260 fish isolate (STIR CD10) was tested by challenging the larvae and incubating at 28°C postinfection with the other strains tested at 37°C. Prior to infection studies, the MIC of each strain to erythromycin, ampicillin and tetracycline was determined by the broth dilution method (Table S1 ).
All strains tested are susceptible to erythromycin and ampicillin with MICs ranging from 0.031 to 0.5 µg/ml. One fish (ST283; STIR CD25), one human (ST8; MRI Z2-137) and two bovine (ST8;
MRI Z2-053 and ST7; MRI Z1-354) isolates were found to be resistant to tetracycline (MIC ranging from 16 to 64 µg/ml) while the other tested strains are susceptible (MICs ranging from 0.125 to 1 µg/ml). Except for those strains identified as resistant to tetracycline, one injection of 20 µg of erythromycin, ampicillin or tetracycline 2 hours post infection, was able to rescue larvae infected by fish, human or bovine isolates (Figure 4) . For those strains resistant to tetracycline survival of Galleria was not significantly different on tetracycline treatment from control larvae treated with PBS. These data indicate an excellent correlation between GBS sensitivity to antibiotics and in vitro and in vivo at both 37°C and 28°C, indicating this model may be useful for testing novel anti-GBS agents.
Discussion
In this work, we demonstrate the utility of G. mellonella larvae as a GBS infection model. Due to the importance of GBS as a human, livestock and aquaculture pathogen and the widespread use of antibiotics to prevent or treat GBS infections there is a pressing need to identify and develop new anti-GBS strategies that could limit the associated spread of antimicrobial resistance. In this respect, invertebrate infection models are very attractive for the screening of new antimicrobials, to compare their efficacy to known antibiotics, or study the effect of antibiotic combinations 37, 38, 33, 35 . To demonstrate the potential to use G. mellonella larvae for in vivo screening of antimicrobials we show antibiotics are able to afford survival to a lethal GBS infection.
Indeed, the systemic injection of commonly used anti-GBS antibiotics, such as erythromycin, ampicillin or tetracycline, in the hemocoel of infected larvae is able to rescue those infected with susceptible strains but not those infected with resistant strains.
Materials and methods
Bacteria and growth conditions
GBS strains used in this study are described in Table 1 . The panel of strains used represent a range of different capsular serotypes and sequence-types found in the three host species (fish, human and bovine). All human isolates originated from urinary tract infections so that potential differences in virulence between isolates within a host species could be associated with ST or serotype rather than clinical origin. Similarly, all bovine isolates originated from the milk of animals with mastitis. Where possible, human and bovine isolates of each ST were included to allow for assessment of host effects within ST. For fish isolates, the range of available STs was limited and represented the major CCs and serotypes known to be associated with fishes (ST7-serotype Ia; ST283-serotype III; CC552-serotype Ib). GBS were stored at -80°C in 25% (v/v) glycerol and cultured in Brain Heart Infusion broth/agar medium (BHI, Oxoid) at 37°C, with the exception of ST260, a member of the poikilothermic CC552, which were grown at 28°C.
Galleria mellonella challenge
G. mellonella larvae were obtained from Livefood UK. They were kept in darkness at room temperature and were used maximum one week following arrival. Healthy larvae with no melanisation were used for all experiments. GBS strains were grown in BHI at 37°C or 28°C to an OD 600 = 0.4 -0.6. Cells were then washed twice in sterile PBS and diluted to the desired inoculum in PBS. Inoculums were serially diluted and plated on BHI agar plates just before administration for CFU counting. For the determination of the LD 50 of GBS strains, 4 groups of 10 larvae were injected with 10 µL of serial dilutions of bacterial suspension in the hemocoel via the last right prolimb. Following challenge, larvae were placed in an incubator at 37°C or at 28°C in the case of ST260 strains. Survival was followed for 48 hours, with health of surviving larvae assessed according to the health scoring index system [14] . Larvae were considered dead when nonresponsive to touch. LD 50 was calculated using the Probit method (XLSTAT software). Survival curves were plotted using the Kaplan-Meier method and differences in survival were calculated using the logrank test (GraphPad Prism 6). Experiments were done at least twice. One representative experiment was shown for survival curves and differences in LD 50 between strains were assessed using Mann-Whitney test. To assess antibiotic efficiency, larvae were challenged with the LD 90 of the GBS strain tested and injected 2 hours post infection with 10 µL of 2 mg/mL erythromycin, ampicillin or tetracycline in the hemocoel via the last left pro-limb. A shaminoculation of PBS was used for untreated control larvae to account for mortality caused by physical injury or infection by a contaminant. Differences in survival rates between treated and untreated larvae were assessed using one-way ANOVA test followed by Dunnett test.
In vivo GBS growth curve
For the in vivo growth curve experiment, larvae were challenged with 10 6 CFU of GBS. At each time point groups of 3 larvae were kept at -20°C for 10 minutes before being transferred to
Eppendorfs containing 100µL of sterile PBS, homogenized, serially diluted and plated on chromogenic selective GBS Brilliance agar (Thermo Scientific, PO5320A). Homogenization was performed using FastPrep lysing matrix M (MPbio).
Immunohistochemistry (IHC) and histological analysis
Larvae were challenged with 10 6 CFU of fish ST283 isolate (MRI Z2-366) as previously described. Uninfected and infected larvae were collected immediately after inoculation, 6h or 12h post challenge and kept at -20°C for up to 10 min before fixation. Whole larvae were placed in 10X
volume of 10% neutral buffer formalin at room temperature for 48h. Longitudinal and cross sections of paraffin-embedded larvae were prepared to detect GBS presence in an early, middle and late phase of challenge. For antigen retrieval, heat induced epitope retrieval (HIER) was 
